Overdiagnosis in early detection programs

Biostatistics

Volumn 5, Issue 4, 2004, Pages 603-613

  Davidov, Ori ^a   Zelen, Marvin ^b  

^a UNIVERSITY OF HAIFA   (Israel)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Early detection programs; Overdiagnosis; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; EARLY DIAGNOSIS; HUMAN; LABORATORY DIAGNOSIS; MALE; MASS SCREENING; MATHEMATICAL COMPUTING; MIDDLE AGED; PREDICTION AND FORECASTING; PROSTATE TUMOR; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; EARLY DIAGNOSIS; FALSE POSITIVE REACTIONS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NUMERICAL ANALYSIS, COMPUTER-ASSISTED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 16644373262     PISSN: 14654644     EISSN: None     Source Type: Journal    
DOI: 10.1093/biostatistics/kxh012     Document Type: Article

References (24)

1. BLACK, W. C. (2000). Overdiagnosis: an under recognized cause of confusion and harm in cancer screening. Journal of the National Cancer Institute 92, 1280-1281.
2. BOSTWICK, D. G. AND CHANG, L. (1999). Overdiagnosis of prostatic adenocarcinoma. Semin Urological Oncology 17, 199-205.
3. CIATTO, S., ZAPPA, M., BONARDI, R. AND GERVASI, G. (2000). Prostate cancer screening, the problem of Overdiagnosis and lessons to be learned from breast cancer screening. European Journal of Cancer 39, 1347-1350.
4. DAVIDOV, O. (1999). The steady state probabilities for regenerative semi Markov processes with application to prevention and screening. Applied Stochastic Models 15, 55-63.
5. DAVIDOV, O. AND ZELEN, M. (2003). The theory of case-control studies for early detection programs. Biostatistics 4, 411-421.
6. DE KONING, H. J., LIEM, M. K., BAAN, C. A., BOER, R., SCHRODER, F. H. AND ALEXANDER, F. E. (2002). Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomized Screening for Prostate Cancer (ERSPC) trial. International Journal of Cancer 98, 268-273.
7. ETZIONI, R., CHA, R., FEUER, E. J. AND DAVIDOV, O. (1998). Asymptomatic incidence and duration in prostate cancer. American Journal of Epidemiology 148, 775-785.
8. ETZIONI, R., PENSON, D. F., LEGLER, J. M., DI TOMMASO, D., BOER, R., GANN, P. H. AND FEUER, E. J. (2002). Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. Journal of the National Cancer Institute 94, 981-990.
9. GANN, P. H., HENNEKENS, C. H. AND STAMPFER, M. J. (1995). A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. Journal of the American Medical Association 273, 289-294.
10. GOHAGAN, J. K., PROROK, P. C., HAYES, R. B., KRAMER, B. S. AND PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER SCREENING TRIAL PROJECT TEAM (2000). The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clinical Trials 21, 251S-272S.
11. HUGOSSON, J., AUS, G., CARLSSON, S., ERIKSSON, H., LILJA, H. AND LODDING, P. (2000). Would prostate cancer detected by screening with prostate specific antigen develop into clinical cancer if left undiagnosed? British Journal of Urology 85, 1078-1084.
12. LEE, S. J. AND ZELEN, M. (1998). Scheduling periodic examinations for the early detection of disease: applications to breast cancer. Journal of the American Statistical Association 93, 1271-1281.
13. MEZZETTI, M. AND ROBERTSON, C. (1999). A hierarchical Baycsian approach to age-specific back calculation of cancer incidence rates. Statistics in Medicine 18, 919-933.
14. MCGREGOR, M., HANLEY, J. A., BOIVIN, J. F. AND MCLEAN, R. G. (1998). Screening for prostate cancer estimating the magnitude of overdetection. Canadian Medical Association Journal 159, 1368-1372.
15. PARMIGIANI, G., SKATES, S. AND ZELEN, M. (2002). Modelling and optimization in early detection programs with a single exam. Biometrics 58, 30-36.
16. PEARSON, J. D. AND CARTER, H. B. (1994). Natural history of changes in prostate specific antigen in early stage prostate cancer. Journal of Urology 154, 1743-1748.
17. PINSKY, P. F. (2001). Estimation and prediction for cancer screening models using deconvolutions and smoothing. Biometrics 57, 389-395.
18. STENMAN, H., HAKAM, M., KNEKT, P., AROMAA, A., TEPPO, L. AND LEINONEN, J. (1994). Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. The Lancet 344, 1594-1598.
19. SMITH, R. A., COKKINIDES, V. AND EYRE, H. J. (2003). American Cancer Society guidelines for the early detection of cancer. CA Cancer Journal Clinical 53, 27-43.
20. SWAN, J., BREEN, N., COATES, R. J., RIEMER, B. K. AND LEE, N. C. (2003). Progress in cancer screening practices in the United States. Results from the 2000 National Health Interview Survey. Cancer 97, 1528-1540.
21. WHITTEMORE, A. S., KELLER, J. B. AND BETENSKY, R. (1991). Low grade latent prostate cancer volume: predictor of cancer incidence? Journal of the National Cancer Institute 83, 1231-1235.
22. WHITTEMORE, A. S., LELE, C. AND FRIEDMAN, G. D. (1995). Prostate specific antigen as a predictor of prostate cancer in black men and white men. Journal of the National Cancer Institute 87, 345-360.
23. ZAPPA, M., CIATTO, S., BONARDI, R. AND MAZZOTTA, A. (1998). Overdiagnosis of prostate carcinoma: an estimate based on the results of the Florence screening pilot study. Annals of Oncology 9, 1297-1300.
24. ZELEN, M. (1993). Optimal scheduling of examinations for the early detection of disease. Biometrika 80, 279-293.